



Year: 2011

Synthesis and selected reactions of hydrazides containing an imidazole moiety

Mlostoń, G ; Pieczonka, A M ; Kowalczyk, E ; Linden, Anthony ; Heimgartner, H

Abstract: The preparation of two types of imidazole derivatives bearing a hydrazide group was achieved by treatment of the corresponding esters with $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ in MeOH at room temperature. In the case of 4-(ethoxycarbonyl)-1H-imidazole 3-oxides 3, hydrazides of type 1 were formed with retention of the N-oxide structure (Scheme 1). Interestingly, due to a strong H-bonding, no deoxygenation of the N-O function could be achieved even by treatment of 3 with Raney-Ni. The second type, 2-[(1H-imidazol-2-yl)sulfanyl]acetohydrazides 2, was obtained from 1H-imidazole-2(3H)-thiones 4 in two steps via S-alkylation with methyl bromoacetate, followed by treatment with $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ (Scheme 2). An imidazole 7, containing both types of hydrazide groups, was prepared analogously from ethyl 2,3-dihydro-2-thioxo-1H-imidazole-4-carboxylate 4d (Scheme 4). Both types of hydrazides, 1 and 2, were transformed successfully to the corresponding acylhydrazones 8 and 9, respectively (Scheme 5). Furthermore, it has been shown that hydrazides of type 1 are useful starting materials for the synthesis of 1,2,4-triazole-3-thiones 11 and 1,3,4-thiadiazole-2-amines 12, bearing an imidazole 3-oxide moiety (Scheme 7).

DOI: <https://doi.org/10.1002/hlca.201100292>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-52668>

Journal Article

Accepted Version

Originally published at:

Mlostoń, G; Pieczonka, A M; Kowalczyk, E; Linden, Anthony; Heimgartner, H (2011). Synthesis and selected reactions of hydrazides containing an imidazole moiety. *Helvetica Chimica Acta*, 94(10):1764-1777.

DOI: <https://doi.org/10.1002/hlca.201100292>

Prof. Dr. H. Heimgartner
Tel. 044 635 4282
Fax 044 635 6836
e-mail: heimgart@oci.uzh.ch

Synthesis and Selected Reactions of Acid Hydrazides Containing an Imidazole Moiety

by **Grzegorz Mlostoń***, **Adam Marek Pieczonka¹⁾**, and **Ewelina Kowalczyk²⁾**

University of Łódź, Department of Organic and Applied Chemistry, Tamka 12, PL-91-
403 Łódź (phone: +48 42 6355761; fax: +48 42 6655162; e-mail:
gmloston@uni.lodz.pl)

and **Anthony Linden** and Heinz **Heimgartner***

Organisch-chemisches Institut der Universität Zürich, Winterthurerstrasse 190,
CH-8057 Zürich (phone: +41 44 6354282; fax: +41 44 6356812; e-mail:
heimgart@oci.uzh.ch)

¹⁾ Part of the planned Ph.D. thesis of *A. M. P.*, University of Łódź.

²⁾ Part of the Diploma thesis of *E. K.*, University of Łódź, 2003.

The preparation of two types of imidazole derivatives bearing a hydrazide group was achieved by treatment of the corresponding esters with $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ in MeOH at room temperature. In the case of 4-(ethoxycarbonyl)imidazole 3-oxides **3**, hydrazides of type **1** were formed with retention of the *N*-oxide structure (*Scheme 1*). Interestingly, due to a strong hydrogen bonding, no deoxygenation of the $\text{N} \rightarrow \text{O}$ function could be achieved even by treatment of **3** with *Raney*-nickel. The second type, 2-[(imidazol-2-yl)sulfanyl]acetohydrazides **2**, was obtained from 1*H*-imidazole-2(3*H*)-thiones **4** in two steps *via* S-alkylation with methyl bromoacetate followed by treatment with $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ (*Scheme 2*). An imidazole **7**, containing both types of hydrazide groups, was prepared analogously from ethyl 2,3-dihydro-2-thioxoimidazole-4-carboxylate **4d** (*Scheme 4*). Both types of hydrazides, **1** and **2**, were transformed successfully into the corresponding acylhydrazones **8** and **9**, respectively (*Scheme 5*). Furthermore, it has been shown that hydrazides of type **1** are useful starting materials for the synthesis of 1,2,4-triazole-3-thiones **11** and 1,3,4-thiadiazole-2-amines **12**, bearing an imidazole 3-oxide residue (*Scheme 7*).

1. Introduction. – In a series of our recent publications, various syntheses of imidazole derivatives including optically active products were reported [1]. It is well documented that some imidazole derivatives such as imidazole *N*-oxides [2], imidazole-2-thiones [3] or 2-sulfanylimidazoles [4] show diverse biological activities. On the other hand, imidazole *N*-oxides were used for the preparation of more complex *N*-heterocycles *via* Pd-catalyzed direct arylation [5], and in the case of optically active derivatives, they were applied as promising ligands for asymmetric allylation of aromatic aldehydes [6].

Acyl hydrazides were widely reported as biologically active compounds, and similar properties were shown for their derivatives, *e.g.*, hydrazones, semicarbazones, and thiosemicarbazones [7]. Furthermore, acid hydrazides are privileged starting materials for the preparation of various heterocycles like 1,2,4-triazoles, 1,3,4-thiadiazoles, 1,3,4-oxadiazoles, etc. [8].

The goal of the present study was the synthesis of acid hydrazides containing differently substituted imidazole moieties starting with corresponding esters described in our recent publications. For the first time, acid hydrazides derived from 3-oxidoimidazole carboxylic acids and the influence of the oxido function on the reactivity of the hydrazide unit and *vice versa* will be reported. In addition, the synthesis of corresponding hydrazones as representative derivatives is presented.

2. Results and Discussion. – For the synthesis of imidazole containing acid hydrazides of types **1** and **2**, the typical protocol based on the treatment of the corresponding ethyl carboxylates with $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ [9] was applied, and the expected products were obtained in high yields.

The imidazole *N*-oxides **3** bearing the ester group at C(4) were easily available from the reaction of 2-hydroxyimino-3-oxobutanoate with the corresponding primary

amine and CH_2O [1g][10]. Treatment with $\text{NH}_2\text{NH}_2\cdot\text{H}_2\text{O}$ in MeOH at room temperature led to the products **1a–1c**, which were obtained as crystalline materials in good yields (*Scheme 1*). Their structures were determined on the basis of their spectroscopic data. The presence of the *N*-oxido function was evidenced by the diagnostic high field shifted H–C(2) signal at 8.60 – 8.37 ppm.

Scheme 1

Finally, the structure of **1b** was established by X-ray crystallography (*Figure*). The N(4)–H group forms bifurcated H-bonds. One interaction is an intramolecular H-bond with the adjacent oxide O(1)-atom to form a loop, which can be described by a graph set motif [12] of S(6). The second interaction is an intermolecular H-bond with the oxide O-atom of a neighboring molecule. This interaction links pairs of molecules related by a centre of inversion into dimers and the motif thus formed can be described by a graph set motif of $\text{R}^2_2(12)$. The same two molecules are also linked by a H-bond between the NH_2 group and the oxide O-atom. The motif in this case is $\text{R}^2_2(14)$. The other H-atom of the NH_2 group forms an intermolecular H-bond with the hydrazide O(2)-atom of a different neighboring molecule. This interaction links these molecules into centrosymmetric dimers and can be described by a graph set motif of $\text{R}^2_2(10)$. The combination of all intermolecular H-bonds links the molecules into two-dimensional layer networks which lie parallel to the (001) plane. The Ph rings from adjacent layers interdigitate.

Figure. *ORTEP Plot* [11] of the molecular structure of **1b** (with 50% probability ellipsoids; arbitrary numbering of the atoms)

Interestingly, in contrast to the ester **3a**, the attempted ‘sulfur-transfer reaction’ [1a] aimed at obtaining of the corresponding imidazole-2-thione from the acid hydrazide **1a** was unsuccessful. Moreover, the typical thermal isomerization of 2-unsubstituted imidazole *N*-oxide derivatives to the corresponding imidazol-2-ones was not achieved even after heating of **1a** in boiling toluene. Finally, the attempted deoxygenation with *Raney*-Ni, which was performed smoothly in many other cases of imidazole *N*-oxides [1c–1e], did not afford the expected products. All these facts point out that the presence of the hydrazide function strongly influences the reactivity of the oxido function, most likely as a result of a strong intramolecular H-bond between the hydrazide N–H and the oxide O-atom.

The second type of acid hydrazides **2** presented in this study was obtained *via S*-alkylation of imidazole-2-thiones **4** with methyl bromoacetate and subsequent conversion of the ester function (*Scheme 2*). A convenient access to the differently substituted starting materials **4** is the so-called ‘sulfur-transfer reaction’ [1a][1e], in which the 2-unsubstituted imidazole *N*-oxide is treated with a cycloaliphatic thioketone. The crystalline hydrazides **2a–2c** were obtained in good yields.

Scheme 2

Another method used for the incorporation of an ester group into the side chain of imidazoles consists of the condensation of α -hydroxyimino ketones with CH₂O and an appropriate α -amino acid ester [1e]. In that case, the ester group is placed in the

α -position of the side chain at N(1). Unexpectedly, by treatment with $\text{NH}_2\text{NH}_2\cdot\text{H}_2\text{O}$, even under very mild conditions, the imidazole *N*-oxides **5a–5b** were converted into the α -(imidazol-1-yl)carboxylic acids **6a–6b** in nearly quantitative yields (*Scheme 3*). The preservation of the *N*-oxide function was confirmed by the ^1H -NMR spectra, which showed the typical absorption for H–C(2) at 8.13 for **2a** and 8.36 ppm for **2b**, respectively.

Scheme 3

Starting with 2-thioxoimidazole-4-carboxylate **4d**, which was obtained in analogy to the corresponding N-Ph amide [1g] by the ‘sulfur-transfer reaction’ with **3b**, subsequent alkylation with methyl bromoacetate and treatment with two equivalents of $\text{NH}_2\text{NH}_2\cdot\text{H}_2\text{O}$ led to the bis-hydrazide **7** (*Scheme 4*). The latter represents an example in which the structure elements of type **1** and type **2** are combined.

Scheme 4

Both types of easily available acid hydrazides, **1** and **2**, are attractive starting materials for further syntheses involving the hydrazide group. In the present study, they were used for the formation of hydrazones with various aldehydes and ketones ³⁾. In the case of acid hydrazides **1b** and **1c**, the reactions with benzaldehyde, adamantan-2-one, and cyclohexanone, respectively, in MeOH occurred smoothly at room temperature and yielded the expected hydrazones **8a–8f** in high yields. The analogous reactions with

³⁾ For some recent articles on synthesis and biological interest of acylhydrazones see [7a][8a][13].

acetophenone required acid catalysis (AcOH in EtOH, reflux) to give **8e** and **8f** (*Scheme 5*), whereas with benzophenone no hydrazone was obtained.

A series of hydrazones of type **9** derived from hydrazides **2a–2c** was prepared by using some of aromatic aldehydes and cyclohexanone. The reactions were carried out in boiling EtOH in the presence of catalytic amounts of AcOH, and in all cases the products were isolated as crystalline materials (*Scheme 5*).

Scheme 5

In contrast to hydrazide **1a**, which did not undergo the ‘sulfur transfer reaction’ upon treatment with 2,2,4,4-tetramethylcyclobutane-1,3-dithione, the analogous reaction with hydrazide hydrazone **8c** afforded, after 24 h at room temperature in CH₂Cl₂, the expected imidazol-2-thione derivative **4e** in 88% yield (*Scheme 6*). It is worth mentioning that corresponding *N*-Me and *N*-Ph-substituted 3-oxidoimidazole-4-carboxamides react under similar conditions [1g], whereas the transformation of 4-methyl- and 4-phenylimidazole-3-oxides is complete within *ca.* 30 min. This result confirms the importance of the H-bonding between the amide and hydrazide function and the N→O group for the tuning of the reactivity of imidazole *N*-oxide as a 1,3-dipol [1a].

Scheme 6

The reaction of acid hydrazides with isothiocyanates is a typical procedure applied for the preparation of 1,3,4-thiadiazoles or 1,2,4-triazole-3-thiones [14]. The two-steep reactions led initially to thiosemicarbazides, which subsequently undergo

cyclocondensation under acidic or basic reaction conditions. Using these methods, hydrazide **1b** was smoothly converted into triazole thione **11** by heating of thiosemicarbazide **10** in aqueous NaOH solution, whereas after stirring of a solution of **1b** in conc. H₂SO₄ at room temperature, thiadiazole **12** was obtained in high yield (*Scheme 7*).

Scheme 7

3. Conclusions. – The presented results show that differently substituted imidazole *N*-oxides containing an ester group can be easily transformed into the corresponding acid hydrazides without loss of the *N*-oxide function. To the best of our knowledge, there are no such examples of azaheterocyclic *N*-oxides reported to date. The presence of the hydrazide function and the *N*-oxide group offer a unique opportunity for their exploration in the synthesis of more complex heterocycles, which are potentially useful building blocks for the preparation of products with biological activity. Some imidazole derivatives containing hydrazide [15] or hydrazone moieties [16] were reported as potential pharmaceuticals, a fact, which is also reflected by several patents, *e.g.* [17].

In addition, imidazole *N*-oxides can be transformed into imidazole-2-thiones, which may be used for syntheses of another class of acid hydrazides containing the imidazole unit. These products can also be considered as potentially useful starting materials for the preparation of diverse polyheterocycles.

Acknowledgment

The authors thank PD Dr. L. Bigler (University of Zurich) for registration of a series of HR-MS spectra. A. P. thanks for financial support within the project co-funded by the European Union under the European Social Fund 'HUMAN – BEST INVESTMENT!'

Experimental Part

1. *General*. M.p.: *Melt-Temp. II* (Aldrich); uncorrected. IR Spectra: *NEXUS FT-IR* spectrophotometer; in KBr; absorptions in cm^{-1} . ^1H - and $^{13}\text{C}\{^1\text{H}\}$ -NMR Spectra: *Bruker Avance III 600* using solvent signal as reference; δ in ppm; coupling constants J in Hz. Assignments of signals in ^{13}C -NMR spectra were made on the basis of HMQC experiments. EI-HR-MS: *Bruker Esquire LC* spectrometer, ESI-HR-MS: *Finnigan MAT-95* instrument. Optical rotations were determined on a *PERKIN-ELMER 241 MC* polarimeter for $\lambda = 589 \text{ nm}$.

2. *Starting Materials*. All solvents are commercially available and were used as received. Imidazole *N*-Oxides **3a,b,c** and **5a,b**, and 1*H*-imidazole-2-thiones **4a–c** were prepared following known procedures [1a][1e]. 2,2,4,4-Tetramethylcyclobutane-1,3-dithione was prepared by thionation of 2,2,4,4-tetramethylcyclobutane-1,3-dione using P_2S_5 as a thionating reagent [18].

3. *General Procedure for the Synthesis of Hydrazides 1*. To a soln. of freshly prepared imidazole *N*-oxide ester **3** (10 mmol) in MeOH (5 ml), was added $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ (20 mmol). The mixture was stirred for 16 h at r.t., the solvent was evaporated under vacuum, and the residue was crystallized from MeOH.

1,5-Dimethyl-3-oxido-1H-imidazole-4-carboxyhydrazide (1a). Yield: 1.02 g (65%). Colorless crystals. M.p. 242–246° (decomp., MeOH). IR (KBr): 3309_s, 3261_s (N–H), 1648_{vs} (C=O), 1601_{vs}, 1530_m, 603_m. ¹H-NMR ((D₆)DMSO): 11.58 (br. *s*, NH); 8.37 (*s*, H–C(2)); 4.49 (br. *s*, NH₂); 3.54 (*s*, MeN); 2.48 (*s*, Me). ¹³C-NMR ((D₆)DMSO): 159.3 (C=O); 133.3, 120.7 (C(4), C(5)); 126.6 (C(2)); 32.2 (MeN); 9.3 (Me). HR-ESI-MS: 171.0874 ([*M*+H]⁺, C₆H₁₁N₄O₂; calc. 171.0876).

1-Benzyl-5-methyl-3-oxido-1H-imidazole-4-carboxyhydrazide (1b): Yield: 1.353 g (55%). Colorless crystals. M.p. 228–230° (decomp., MeOH). IR (KBr): 3296_{vs} (NH), 1661_{vs} (C=O), 1604_{vs}, 1579_m, 977_m. ¹H-NMR ((D₆)DMSO): 11.57 (br. *s*, NH); 8.60 (*s*, H–C(2)); 7.40–7.21 (*m*, 5 arom. H); 5.21 (*s*, CH₂); 4.51 (br. *s*, NH₂); 2.42 (*s*, Me). ¹³C-NMR ((D₆)DMSO): 159.2 (C=O); 136.0, 121.3 (C(4), C(5)); 130.0 (1 arom. C); 129.4, 128.6, 127.6 (5 arom. CH); 126.6 (C(2)); 48.6 (CH₂); 9.6 (Me). HR-ESI-MS: 247.1191 ([*M*+H]⁺, C₁₂H₁₅N₄O₂; calc. 247.1190).

1-Cyclohexyl-5-methyl-3-oxido-1H-imidazole-4-carboxyhydrazide (1c): Yield: 1.428 g (60%). Colorless crystals. M.p. 170–172° (MeOH). IR (KBr): 3305_s, 3271_s (NH), 1655_{vs} (C=O), 1600_{vs}, 1544_m, 1416_m, 1281_m. ¹H-NMR ((D₆)DMSO): 11.63 (br. *s*, NH); 8.58 (*s*, H–C(2)); 4.49 (br. *s*, NH₂); 4.09–4.00 (*m*, CH); 2.55 (*s*, Me); 1.96–1.76 (*m*, 4 cyclohexyl H); 1.70–1.57 (*m*, 3 cyclohexyl H); 1.46–1.35 (*m*, 2 cyclohexyl H); 1.22–1.11 (*m*, 1 cyclohexyl H). ¹³C-NMR ((D₆)DMSO): 159.4 (C=O); 129.2, 120.3 (C(4), C(5)); 124.2 (C(2)); 55.0 (CH); 33.0, 25.4, 25.0 (5 cyclohexyl CH₂); 9.33 (Me). HR-EI-MS: 239.1494 ([*M*+H]⁺, C₁₁H₁₉N₄O₂; calc. 239.1502).

Treatment of ethyl α-(imidazol-1-yl)carboxylates **5** with NH₂NH₂·H₂O following the same procedure led to the corresponding carboxylic acids **6**.

(S)-2-(4,5-Dimethyl-3-oxido-1H-imidazol-1-yl)propanoic Acid (6a). Yield: 1.656 g (90%). Yellowish oil. [α]_D²⁰ = +74 (*c* = 1, MeOH). IR (film): 1683_{vs} (C=O),

1633 m , 1568 m , 1410 m , 1337 m . $^1\text{H-NMR}$ (CD_3OD): 8.18 (s , $\text{H-C}(2')$); 4.63 (q , $J = 7.2$, CH); 2.16, 2.15 ($2s$, 2 Me); 1.68 (d , $J = 7.2$, Me). $^{13}\text{C-NMR}$ (CD_3OD): 174.8 (C=O); 124.8, 122.7 ($\text{C}(4')$, $\text{C}(5')$); 124.3 ($\text{C}(2')$); 57.0 (CH); 17.2 (Me); 7.3, 5.6 (2 imidazole Me). HR-EI-MS: 185.0921 ($[\text{M}+\text{H}]^+$, $\text{C}_8\text{H}_{13}\text{N}_2\text{O}_3$; calc. 185.0927).

(*S*)-2-(4,5-Dimethyl-3-oxido-1H-imidazol-1-yl)-3-methylbutanoic Acid (**6b**).

Yield: 1.844 g (87%). Yellowish oil. $[\alpha]_{\text{D}}^{20} = +34$ ($c = 1$, MeOH). IR (film): 1671 ν_{s} (br. C=O), 1633 m , 1558 m , 1411 m , 1333 m . $^1\text{H-NMR}$ (CD_3OD): 8.36 (s , $\text{H-C}(2')$); 4.21 (d , $J = 10.6$, CHN); 2.42–2.35 (m , CH); 2.22, 2.15 ($2s$, 2 Me); 1.03 (d , $J = 6.5$, Me); 0.83 (d , $J = 7.1$, Me). $^{13}\text{C-NMR}$ (CD_3OD): 178.8 (C=O); 125.2, 122.6 ($\text{C}(4')$, $\text{C}(5')$); 124.8 ($\text{C}(2')$); 63.5 (CHN); 31.9 (CH); 17.9, 17.6 (2 Me); 7.4, 5.6 (2 imidazole Me). HR-EI-MS: 213.1232 ($[\text{M}+\text{H}]^+$, $\text{C}_{10}\text{H}_{17}\text{N}_2\text{O}_3$; calc. 213.1240).

4. *General Procedure for the Synthesis of Hydrazides 2*. To a soln. of an imidazole-2-thione **4** (1 mmol) in CH_2Cl_2 (5 ml) was added methyl bromoacetate (1 mmol). The mixture was stirred for 48 h at r.t., then, the solvent was evaporated under vacuum, and the residue was used immediately without further purification. The oily residue was dissolved in EtOH (5 ml) and $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ (2 mmol) was added. The mixture was heated under reflux for 2 h, the solvent was evaporated under vacuum, and the residue was crystallized from MeOH.

2-[(1-Benzyl-4,5-dimethylimidazol-2-yl)sulfanyl]acetohydrazide (**2a**). Yield: 0.225 g (88%). Colorless crystals. M.p. 127–129° (MeOH). IR (KBr): 3321 s (NH), 1671 ν_{s} (C=O), 1420 m , 722 m . $^1\text{H-NMR}$ (CDCl_3): 9.88 (br. s , NH); 7.26–6.91 (m , 5 arom. H); 4.99 (s , CH_2N); 3.48 (s , CH_2S); 2.10, 1.96 ($2s$, 2 Me). $^{13}\text{C-NMR}$ (CDCl_3): 170.2 (C=O); 138.6 ($\text{C}(2')$); 136.0, 134.6, 125.3 (1 arom. C, $\text{C}(4')$, $\text{C}(5')$); 129.0, 127.9, 126.2 (5 arom. CH); 47.9 (CH_2N); 35.4 (CH_2S); 12.7, 9.2 (2 Me). HR-EI-MS: 291.1275 ($[\text{M}+\text{H}]^+$, $\text{C}_{14}\text{H}_{19}\text{N}_4\text{OS}$; calc. 291.1280).

2-[(1-Cyclohexyl-4,5-dimethylimidazol-2-yl)sulfanyl]acetohydrazide (**2b**).

Yield: 0.212 g (75%). Colorless crystals. M.p. 117–119° (MeOH). IR (KBr): 3314*s*, 3226*s* (br., NH), 1676*vs* (C=O), 1615*vs*, 1523*m*, 1413*m*, 1003*m*. ¹H-NMR (CDCl₃): 10.0 (br. *s*, NH); 3.97–3.93 (*m*, CH); 3.63 (*s*, CH₂S); 2.16, 2.11 (2*s*, 2 Me); 2.03–1.71 (*m*, 7 cyclohexyl H); 1.39–1.18 (*m*, 3 cyclohexyl H). ¹³C-NMR (CDCl₃): 170.5 (C=O); 137.9 (C(2')); 134.2, 124.6 (C(4'), C(5')); 57.2 (CH); 35.2 (CH₂S); 31.7, 26.2, 25.2 (5 cyclohexyl CH₂); 12.6, 10.6 (2 Me). HR-EI-MS: 283.1589 ([*M*+H]⁺, C₁₃H₂₃N₄OS; calc. 283.1588).

2-[(1-Benzyl-4,5-diphenylimidazol-2-yl)sulfanyl]acetohydrazide (**2c**). Yield:

0.323 g (76%). Colorless crystals. M.p. 112–115° (MeOH). IR (KBr): 3329*s*, 3276*s* (NH), 1673*vs* (C=O), 1601*vs*, 1453*m*, 1436*m*, 701*m*. ¹H-NMR (CDCl₃): 9.96 (br. *s*, NH); 7.38–6.82 (*m*, 15 arom. H); 4.90 (*s*, CH₂N); 3.67 (*s*, CH₂N). ¹³C-NMR (CDCl₃): 170.2 (C=O); 142.3, 131.1, 129.2 (3 arom. C); 138.2, 133.5 (C(4'), C(5')); 136.0 (C(2')); 131.0, 130.1, 129.1, 128.8, 128.6, 127.9, 126.8, 126.6, 126.4 (15 arom. CH); 48.1 (CH₂N); 34.6 (CH₂S). HR-EI-MS: 415.1583 ([*M*+H]⁺, C₂₄H₂₃N₄OS; calc. 415.1588).

5. General Procedure for the Synthesis of 1*H*-Imidazole-2-thiones 4. To a magnetically stirred soln. of 1*H*-imidazole N-oxide (1 mmol) in CH₂Cl₂ (1 ml), a soln. of 2,2,4,4-tetramethylcyclobutane-1,3-dithione [18][19] (0.6 mmol) in CH₂Cl₂ (1 ml) was added dropwise. The addition was complete after *ca.* 10 min, and stirring was continued for 24 h, while a little precipitate was formed. Then, the solvent was removed under reduced pressure, the resulting solid was washed with hexane, and filtered. The crude product was recrystallized from MeOH.

*Ethyl 1-Benzyl-5-methyl-2-thioxo-1*H*-imidazole-4-carboxylate* (**4d**). Yield:

0.146 g (53%). Colorless crystals. M.p. 205–207° (decomp., MeOH). IR (KBr): 1706*vs*

(C=O), 1417 ν s, 1335 m , 721 m . $^1\text{H-NMR}$ ((D₆)DMSO): 12.87 (br. s , NH); 7.35–7.21 (m , 5 arom. H); 5.36 (s , CH₂); 4.22 (q , J = 7.1, MeCH₂O); 2.28 (s , Me); 1.26 (t , J = 7.1, MeCH₂O). $^{13}\text{C-NMR}$ ((D₆)DMSO): 164.3 (C=S); 159.1 (C=O); 136.6, 115.8 (C(4), C(5)); 135.4 (1 arom. C); 129.1, 127.9, 127.2 (5 arom. CH); 60.9 (MeCH₂O); 47.0 (CH₂); 14.5 (MeCH₂O); 10.9 (Me). HR-ESI-MS: ($[M+H]^+$, C₁₄H₁₇N₂O₂S; calc. 227.1005).

N-(2-Adamantylidenamino)-1-benzyl-5-methyl-2-thioxo-1H-imidazole-4-carboxamide (**4e**). Yield: 0.345 g (88%). Colorless crystals. M.p. 284–286° (decomp., MeOH). IR (KBr): 3293 s (NH), 3140 s , 3063 s , 1616 ν s (C=O), 1510 m , 1496 m , 1406 m , 1365 m . $^1\text{H-NMR}$ (D₆)DMSO): 12.78 (br. s , NH); 9.99 (br. s , imidazol NH); 7.36–7.23 (m , 5 arom. H); 5.34 (s , CH₂); 3.32, 2.55 (2br. s , 2 adamantyl CH); 2.28 (br. s , Me); 1.99–1.75 (m , 12 adamantyl H). $^{13}\text{C-NMR}$ ((D₆)DMSO): 162.5 (C=O); 155.5 (C=S); 136.8 (C=N); 133.3, 117.9 (C(4), C(5)); 130.0 (1 arom. C); 129.1, 127.9, 127.3 (5 arom. CH); 46.9 (CH₂); 39.1, 37.8, 36.3, 31.6, 27.6 (9 adamantyl C); 10.7 (Me). HR-ESI-MS: 395.1895 ($[M+H]^+$, C₂₂H₂₇N₄O₂S; calc. 395.1900).

6. *Synthesis of 1-Benzyl-2-[(2-hydrazino-2-oxoethyl)sulfanyl]-5-methylimidazole-4-carboxyhydrazide (7)*. To a soln. of imidazole-2-thione **4d** (267 mg, 1 mmol) in CH₂Cl₂ (5 ml) was added methyl bromoacetate (153 mg, 1 mmol). The mixture was stirred for 48 h at r.t., the solvent was evaporated under vacuum, and the residue was used for the following reaction without further purification. The oily residue was dissolved in EtOH (5 ml) and NH₂NH₂·H₂O (2 mmol) was added. The mixture was stirred for 16 h at r.t., the solvent was evaporated under vacuum, and the residue was crystallized from MeOH. Yield of **7**: 0.293 g (88%). Colorless crystals. M.p. 194–198° (MeOH). IR (KBr): 3315 ν s (N–H), 3203 m , 1664 ν s (C=O), 1612 ν s, 1594 m , 1495 m , 734 m . $^1\text{H-NMR}$ (CDCl₃): 9.26, 8.99 (2br. s , 2 NH); 7.36–7.05 (m , 5

arom. H); 5.15 (s, CH₂N); 4.30 (br. s, 2 NH₂); 3.73 (s, CH₂S); 2.38 (s, Me). ¹³C-NMR (CDCl₃): 167.3, 162.9 (2 C=O); 140.3, 131.0 (C(4), C(5)); 136.6 (C(2)); 133.9 (1 arom. C); 129.3, 128.1, 126.9 (5 arom. CH); 47.2 (CH₂N); 35.1 (CH₂S); 10.0 (Me). HR-EI-MS: 335.1286 ([M+H]⁺, C₁₄H₁₉N₆O₂S; calc. 335.1285).

7. *General Procedure for the Synthesis of 8a–8f.* To a stirred soln. of a hydrazide **1** (1 mmol) in MeOH (4 ml) at 20°, an equimolar quantity of the carbonyl component (benzaldehyde, adamantan-2-one, cyclohexanone) was added slowly. The mixture was stirred for 16 h at r.t., the soln. was concentrated, the resulting solid was treated with Et₂O, filtered, and crystallized from MeOH.

1-Benzyl-N-(benzylidenamino)-5-methyl-3-oxido-1H-imidazole-4-carboxamide (8a). Yield: 0.308 g (92%). Colorless crystals. M.p. 232–234° (decomp., MeOH). IR (KBr): 3086m, 1667vs (C=O), 1607vs, 1594m, 1558m, 1461m. ¹H-NMR (CDCl₃): 13.80 (br. s, NH); 8.20 (s, H–C=N); 7.79–7.77 (m, 2 arom. H; H–C(2)); 7.41–7.15 (m, 8 arom. H); 5.07 (s, CH₂); 2.67 (s, Me). ¹³C-NMR (CDCl₃): 156.3 (C=O); 149.0 (C=N); 134.1, 122.2 (C(4), C(5)); 133.0, 132.2 (2 arom. C); 130.3, 129.6, 129.3, 128.6, 127.8, 127.3 (10 arom. CH); 125.3 (C(2)); 49.6 (CH₂); 9.8 (Me). HR-ESI-MS: 335.1503 ([M+H]⁺, C₁₉H₁₉N₄O₂; calc. 335.1503).

N-(Benzylidenamino)-1-cyclohexyl-5-methyl-3-oxido-1H-imidazole-4-carboxamide (8b). Yield: 0.229 g (70%). Colorless crystals. M.p. 206–208° (decomp., MeOH). IR (KBr): 3109m, 1671vs (C=O), 1608vs, 1592m, 1417m, 1270m. ¹H-NMR (CDCl₃): 13.89 (br. s, NH); 8.21 (s, H–C=N); 7.85 (s, H–C(2)); 7.80–7.78 (m, 2 arom. H); 7.39–7.37 (m, 3 arom. H); 3.98–3.93 (m, CHN); 2.70 (s, Me); 2.09–1.96 (m, 4 cyclohexyl H); 1.70–1.42 (m, 5 cyclohexyl H); 1.30–1.23 (m, 1 cyclohexyl H). ¹³C-NMR (CDCl₃): 156.5 (C=O); 148.8 (C=N); 134.2 (1 arom. C); 131.2, 121.4 (C(4), C(5)); 130.2, 128.6, 127.8 (5 arom. CH); 122.6 (C(2)); 55.7 (CH); 33.7, 25.4, 24.9 (5

cyclohexyl CH₂); 9.6 (Me). HR-ESI-MS: 327.1816 ($[M+H]^+$, C₁₈H₂₃N₄O₂; calc. 327.1816).

N-(2-Adamantylidenamino)-1-benzyl-5-methyl-3-oxido-1H-imidazole-4-carboxamide (**8c**). Yield: 0.302 g (80%). Colorless crystals. M.p. 260–262° (decomp., MeOH). IR (KBr): 3181 m (NH), 3042 m , 1682 vs (C=O), 1602 vs , 1547 m , 1255 m . ¹H-NMR (CDCl₃): 13.35 (br. s , NH); 7.76 (s , H–C(2)); 7.41–7.38 (m , 3 arom. H); 7.13–7.12 (m , 2 arom. H); 5.07 (s , CH₂); 3.23, 2.87 (2br. s , 2 adamantyl CH); 2.64 (s , Me); 2.05–1.80 (m , 12 adamantyl H). ¹³C-NMR (CDCl₃): 168.5 (C=O); 156.1 (C=N); 133.1, 122.7 (C(4), C(5)); 131.8 (1 arom. C); 129.6, 129.2, 127.1 (5 arom. CH); 125.0 (C(2)); 49.5 (CH₂); 39.4, 39.1, 37.9, 36.4, 32.8, 27.8 (9 adamantyl C); 9.8 (Me). HR-ESI-MS: 379.2132 ($[M+H]^+$, C₂₂H₂₇N₄O₂; calc. 379.2128).

N-(2-Adamantylidenamino)-1-cyclohexyl-5-methyl-3-oxido-1H-imidazole-4-carboxamide (**8d**). Yield: 0.260 g (70%). Colorless crystals. M.p. 226–228° (decomp., MeOH). IR (KBr): 3104 w (NH), 1679 vs (C=O), 1596 vs , 1416 m . ¹H-NMR (CDCl₃): 13.47 (br. s , NH); 7.77 (s , H–C(2)); 3.96–3.90 (m , CHN); 3.22, 2.85 (2br. s , 2 adamantyl CH); 2.68 (s , Me); 2.09–2.02 (m , 2 cyclohexyl H); 2.01–1.82 (m , 12 adamantyl H, 1 cyclohexyl H); 1.81–1.75 (m , 2 cyclohexyl H); 1.57–1.38 (m , 4 cyclohexyl H); 1.30–1.21 (m , 1 cyclohexyl H). ¹³C-NMR (CDCl₃): 168.1 (C=O); 156.5 (C=N); 130.7, 121.9 (C(4), C(5)); 122.4 (C(2)); 55.6 (CHN); 39.4, 39.3, 39.1, 37.9, 36.4, 33.7, 32.7, 27.8, 25.4, 24.8 (9 adamantyl C, 5 cyclohexyl C); 9.5 (Me). HR-ESI-MS: 371.2441 ($[M+H]^+$, C₂₁H₃₁N₄O₂; calc. 371.2442).

I-Benzyl-N-(cyclohexylidenamino)-5-methyl-3-oxido-1H-imidazole-4-carboxamide (**8e**). Yield: 0.320 g (98%). Colorless crystals. M.p. 220–222° (decomp., MeOH). IR (KBr): 3081 s , 2930 s , 1667 vs (C=O), 1602 vs , 1559 m , 1452 m . ¹H-NMR (CDCl₃): 13.46 (br. s , NH); 7.77 (s , H–C(2)); 7.40–7.38 (m , 3 arom. H); 7.13–7.11 (m , 2

arom. H); 5.06 (s, CH₂); 2.63 (s, Me); 2.63–2.43 (m, 4 cyclohexyl H); 1.73–1.67 (m, 4 cyclohexyl H); 1.64–1.60 (m, 2 cyclohexyl H). ¹³C-NMR (CDCl₃): 161.8 (C=O); 156.1 (C=N); 133.1, 122.6 (C(4), C(5)); 131.8 (1 arom. C); 129.5, 129.2, 127.1 (5 arom. CH); 125.1 (C(2)); 49.5 (CH₂); 35.4, 28.1, 27.0, 26.1, 25.7 (5 cyclohexyl C); 9.8 (Me). HR-ESI-MS: 327.1814 ([M+H]⁺, C₁₈H₂₃N₄O₂; calc. 327.1816).

1-Cyclohexyl-N-(cyclohexylidenamino)-5-methyl-3-oxido-1H-imidazole-4-carboxamide (8f). Yield: 0.239 g (75%). Colorless crystals. M.p. 218–220° (decomp., MeOH). IR (KBr): 3084m, 2931vs, 1685vs (C=O), 1596vs, 1538m, 1416m, 1261m. ¹H-NMR (CDCl₃): 13.47 (br. s, NH); 7.82 (s, H-C(2)); 3.97–3.91 (m, CHN); 2.68 (s, Me); 2.46–2.43 (m, 4 cyclohexyl H); 2.07–2.05 (m, 2 cyclohexyl H); 1.97–1.95 (m, 2 cyclohexyl H); 1.78–1.66 (m, 5 cyclohexyl H); 1.65–1.60 (m, 2 cyclohexyl H); 1.58–1.39 (m, 4 cyclohexyl H); 1.30–1.21 (m, 1 cyclohexyl H). ¹³C-NMR (CDCl₃): 161.5 (C=O); 156.3 (C=N); 130.8, 121.8 (C(4), C(5)); 122.5 (C(2)); 55.6 (CHN); 35.5, 33.7, 28.1, 27.0, 26.1, 25.7, 25.4, 24.8 (10 cyclohexyl C); 9.54 (Me). HR-ESI-MS: 319.2129 ([M+H]⁺, C₁₇H₂₇N₄O₂; calc. 319.2128).

8. *General Procedure for the Synthesis of 8g,h and 9a–g*: A soln. of hydrazide **1** or **2** (1 mmol) in EtOH (4 ml) and an equimolar amount of the carbonyl component (4-methoxy-, 4-dimethylamino-, 4-methylsulfanylbenzaldehyde, cyclohexanone) and a catalytic amount of AcOH was heated to reflux for 4 h. After cooling to r.t., the solvent was evaporated under reduced pressure, the residue was dissolved in CH₂Cl₂ and, after addition of NaHCO₃, stirred for 0.5 h. The mixture was filtered, the solvent evaporated under reduced pressure, and the residue was purified by crystallization from MeOH.

1-Benzyl-5-methyl-3-oxido-N-(1-phenylethylidenamino)-1H-imidazole-4-carboxamide (8g). Yield: 0.261 g (76%). Colorless crystals. M.p. 222–226° (decomp., MeOH). IR (KBr): 3061m, 2914m, 1678vs (C=O), 1602vs, 1546m, 1269m, 705m. ¹H-

NMR (CDCl₃): 13.71 (br. *s*, NH); 7.90–7.88 (*m*, 2 arom. H); 7.82 (*s*, H–C(2)); 7.42–7.36 (*m*, 6 arom. H); 7.16–7.14 (*m*, 2 arom. H); 5.09 (*s*, CH₂); 2.67 (*s*, imidazole Me); 2.39 (*s*, MeC=N). ¹³C-NMR (CDCl₃): 156.2 (C=O); 153.0 (C=N); 138.1, 132.1 (2 arom. C); 133.0, 122.6 (C(4), C(5)); 129.6, 129.4, 129.3, 128.2, 127.2, 126.8 (12 arom. C); 125.2 (C(2)); 49.6 (CH₂); 14.5 (*Me*C=N); 9.8 (imidazole Me). HR-ESI-MS: 349.1664 ([*M*+H]⁺, C₂₀H₂₁N₄O₂; calc. 349.1659).

1-Cyclohexyl-5-methyl-3-oxido-N-(1-phenylethylidenamino)-1H-imidazole-4-carboxamide (8h). Yield: 0.238 g (70%). Colorless crystals. M.p. 264–268° (decomp., MeOH). IR (KBr): 3080*m*, 2937*s*, 1675*vs* (C=O), 1601*vs*, 1553*m*, 1417*m*, 1273*m*. ¹H-NMR (CDCl₃): 13.67 (br. *s*, NH); 7.94–7.92 (*m*, 2 arom. H, H–C(2)); 7.41–7.39 (*m*, 3 arom. H); 4.03–3.98 (*m*, CHN); 2.75 (*s*, imidazole Me); 2.43 (*s*, MeC=N); 2.14–2.00 (*m*, 4 cyclohexyl H); 1.64–1.45 (*m*, 4 cyclohexyl H); 1.34–1.25 (*m*, 2 cyclohexyl H). ¹³C-NMR (CDCl₃): 156.2 (C=O); 152.9 (C=N); 138.1 (1 arom. C); 131.2, 121.8 (C(4), C(5)); 129.4, 128.2, 126.8 (5 arom. CH); 122.8 (C(2)); 55.8 (CHN); 33.7, 25.4, 24.8 (5 cyclohexyl C); 14.5 (*Me*C=N); 9.6 (Me). HR-ESI-MS: 341.1975 ([*M*+H]⁺, C₁₉H₂₅N₄O₂; calc. 341.1972).

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)sulfanyl-N-[(4-methoxyphenyl)methylenamino]acetamide (9a). Yield: 0.237 g (57%). Colorless crystals. M.p. 130–132° (MeOH). IR (KBr): 3186*m* (br.), 3067*m* (br.), 1664*vs* (C=O), 1606*vs*, 1407*m*, 1245*m*. ¹H-NMR (CDCl₃): 12.82 (br. *s*, NH); 8.12 (*s*, H–C=N); 7.72–6.89 (*m*, 9 arom. H); 5.08 (*s*, CH₂N); 3.84 (*s*, MeO); 3.61 (*s*, CH₂S); 2.24, 2.05 (2*s*, 2 imidazole Me). ¹³C-NMR (CDCl₃): 166.0 (C=O); 161.4 (C=N); 147.8 (arom. C–O); 139.3 (C(2')); 135.9, 125.5 (C(4'), C(5')); 134.1 (1 arom. C); 129.3, 129.0, 128.0, 126.6, 126.3, 114.1 (10 arom. C); 55.4 (MeO); 48.1 (CH₂N); 36.3 (CH₂S); 12.7, 9.2 (2 imidazole Me). HR-ESI-MS: 409.1701 ([*M*+H]⁺, C₂₂H₂₄N₄O₂S; calc. 409.1694).

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)sulfanyl-N-[(4-dimethylaminophenyl)methylenamino]acetamide (9b). Yield: 0.337 (80%). Colorless crystals. M.p. 75–79° (MeOH). IR (KBr): 3203*m* (br.), 3023*m* (br.), 2917*s* (br.), 1679*vs* (C=O), 1608*vs*, 1525*m*, 1360*m*, 1180*m*. ¹H-NMR (CDCl₃): 12.52 (br. *s*, NH); 8.05 (*s*, H–C=N); 7.64–6.66 (*m*, 9 arom. H); 5.07 (*s*, CH₂N); 3.60 (*s*, CH₂S); 3.01 (*s*, Me₂N); 2.23, 2.04 (2*s*, 2 imidazole Me). ¹³C-NMR (CDCl₃): 165.6 (C=O); 151.9 (C=N); 148.8 (arom. C–N); 139.3 (C(2')); 135.9 (1 arom. C); 134.2, 121.6 (C(4'), C(5')); 129.2, 129.0, 127.9, 126.32, 126.29, 111.6 (10 arom. C); 48.0 (CH₂N); 40.2 (Me₂N); 36.3 (CH₂S); 12.7, 9.2 (2 imidazole Me). HR-EI-MS: 422.2009 ([*M*+H]⁺, C₂₃H₂₈N₅OS; calc. 422.2010).

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)sulfanyl-N-(cyclohexylidenamino)acetamide (9c). Yield: 0.322 g (87%). Colorless crystals. M.p. 124–130° (MeOH). IR (KBr): 3207*m* (br., NH), 3061*m* (br.), 1667*vs* (C=O), 1406*m*, 718*m*. ¹H-NMR (CDCl₃): 11.81 (br. *s*, NH); 7.33–6.99 (*m*, 5 arom. H); 5.04 (*s*, CH₂N); 3.61 (*s*, CH₂S); 2.54–2.42 (*m*, 4 cyclohexyl H); 2.12, 2.03 (2*s*, 2 imidazole Me); 1.75–1.61 (*m*, 6 cyclohexyl H). ¹³C-NMR (CDCl₃): 166.7 (C=O); 160.9 (C=N); 140.0 (C(2')); 135.9 (1 arom. C); 134.1, 125.2 (C(4'), C(5')); 129.0, 127.9, 126.2 (5 arom. CH); 48.0 (CH₂N); 36.2 (CH₂S); 35.4, 28.3, 27.0, 26.1, 25.7 (5 cyclohexyl CH₂); 12.6, 9.2 (2 imidazole Me). HR-EI-MS: 371.1879 ([*M*+H]⁺, C₂₀H₂₇N₄OS; calc. 371.1901).

2-(1-Cyclohexyl-4,5-dimethylimidazol-2-yl)sulfanyl-N-[(4-methylsulfanylphenyl)methylenamino]acetamide (9d). Yield: 0.152 g (37%). Colorless crystals. M.p. 76–78° (MeOH). IR (KBr): 3296*m*, (br., NH), 3058*m*, 1667*vs* (C=O), 1596*vs*, 1505*m*, 1363*m*. ¹H-NMR (CDCl₃): 13.11 (br. *s*, NH); 8.05 (*s*, H–C=N); 7.66–7.21 (*m*, 4 arom. H); 3.99–3.95 (*m*, CHN); 3.70 (*s*, CH₂S); 2.49 (*s*, MeS); 2.19, 2.18 (2*s*, 2 imidazole Me); 2.05–1.72 (*m*, 7 cyclohexyl H); 1.42–1.18 (*m*, 3 cyclohexyl H). ¹³C-NMR (CDCl₃): 166.5 (C=O); 147.2 (C=N); 141.6 (C(2')); 138.6, 130.6 (C(4'), C(5')); 134.9

(1 arom. C); 128.0, 125.8, 124.8 (5 arom. C); 57.4 (CHN); 36.2 (CH₂S); 31.7, 26.2, 25.2 (5 cyclohexyl CH₂); 15.2 (MeS); 12.7, 10.5 (2 imidazole Me). HR-EI-MS: 417.1767 ($[M+H]^+$, C₂₁H₂₉N₄OS₂; calc. 417.1778).

2-(1-Cyclohexyl-4,5-dimethylimidazol-2-yl)sulfanyl-N-[(4-methoxyphenyl)methylenamino]acetamide (9e). Yield: 0.288 g (72%). Colorless crystals. M.p. 96–102° (MeOH). IR (KBr): 3203 m (br., NH), 2917 s (br.), 1664 vs (C=O), 1607 vs , 1512 m , 1418 m , 1307 m , 1250 m . ¹H-NMR (CDCl₃): 12.96 (br. s , NH); 8.05 (s , H–C=N); 7.69–6.86 (m , 4 arom. H); 3.99–3.96 (m , CHN); 3.83 (s , MeO); 3.70 (s , CH₂S); 2.19, 2.18 (2 s , 2 imidazole Me); 2.05–1.74 (m , 7 cyclohexyl H); 1.42–1.18 (m , 3 cyclohexyl H). ¹³C-NMR (CDCl₃): 166.4 (C=O); 147.6 (C=N); 147.6 (1 arom. C–O); 141.6, 126.7 (C(4'), C(5')); 138.6 (C(2')); 129.3, 124.7, 114.1 (5 arom. C); 57.4 (CHN); 55.3 (MeO); 36.2 (CH₂S); 31.7, 26.2, 25.2 (5 cyclohexyl CH₂); 12.6, 10.5 (2 imidazole Me). HR-EI-MS: 401.1986 ($[M+H]^+$, C₂₁H₂₉N₄O₂S; calc. 401.2007).

2-(1-Benzyl-4,5-diphenylimidazol-2-yl)sulfanyl-N-[(4-methylsulfanylphenyl)methylenamino]acetamide (9f). Yield: 0.390 g (71%). Colorless crystals. M.p. 154–156° (MeOH). IR (KBr): 3296 m (br., NH), 3058 m (br.), 1683 vs (C=O), 1596 vs , 1433 m , 702 m . ¹H-NMR (CDCl₃): 12.90 (br. s , NH); 7.87 (s , H–C=N); 7.50–6.92 (m , 19 arom. H); 5.01 (s , CH₂N); 3.83 (s , CH₂S); 2.47 (s , MeS). ¹³C-NMR (CDCl₃): 165.9 (C=O); 148.1 (C=N); 143.1, 141.7, 131.2, 129.7 (4 arom. C); 137.9, 133.6 (C(4'), C(5')); 135.8 (C(2')); 130.9, 130.4, 129.3, 129.2, 128.9, 128.5, 128.01, 127.98, 127.1, 126.6, 126.5, 125.8 (1 arom. C, 19 arom. CH); 48.3 (CH₂N); 35.6 (CH₂S); 15.2 (MeS). HR-EI-MS: 549.1770 ($[M+H]^+$, C₃₂H₂₉N₄OS₂; calc. 549.1778).

2-(1-Benzyl-4,5-diphenylimidazol-2-yl)sulfanyl-N-(cyclohexylidenamino)acetamide (9g). Yield: 0.329 g (67%). Colorless crystals. M.p. 166–168° (MeOH). IR (KBr): 3321 s (br., NH), 3026 m , 1679 vs (C=O), 1602 vs , 1453 m , 1433 m , 701 m . ¹H-NMR

(CDCl₃): 11.38 (br. s, NH); 7.36–6.92 (*m*, 15 arom. H); 4.97 (*s*, CH₂N); 3.93 (*s*, CH₂S); 2.34–1.93 (*m*, 4 cyclohexyl H); 1.62–1.03 (6 cyclohexyl H). ¹³C-NMR (CDCl₃): 166.3 (C=O); 161.4 (C=N); 143.6, 131.2 (C(4'), C(5')); 135.7 (C(2')); 131.0, 130.9, 129.7, 129.0, 128.8, 128.3, 128.2, 127.9, 126.9, 126.7, 126.6 (3 arom. C, 15 arom. CH); 48.3 (CH₂N); 35.3 (CH₂S); 34.6, 27.8, 26.7, 25.4, 25.3 (5 cyclohexyl CH₂). HR-EI-MS: 495.2207 ([*M*+H]⁺, C₃₀H₃₁N₄OS; calc. 495.2214).

9. *Synthesis of 1-[(1-Benzyl-5-methyl-3-oxidoimidazolium-4-yl)-4-carbonyl]amino-3-methylthiourea (10)*: A mixture of **1b** (247 mg, 1 mmol) and methyl isothiocyanate (80 mg, 1.1 mmol) in EtOH (5 ml) was heated to reflux for 2 h. The formed product **10** was then filtered off, washed with Et₂O, and crystallized from MeOH. Yield: 0.257 g (90%). Colorless crystals. M.p. 224–228° (MeOH). IR (KBr): 3271_{vs} (NH), 3097_s (br.), 1682_{vs} (C=O), 1599_{vs}, 1557_m, 740_m. ¹H-NMR ((D₆)DMSO): 12.39, 9.34 (2br. *s*, 2 NH); 8.71 (*s*, H–C(2)); 8.00 (br. *s*, NH); 7.42–7.24 (*m*, 5 arom. H); 5.25 (*s*, CH₂N); 2.85 (*d*, *J* = 4.3, Me); 2.43 (*s*, Me). ¹³C-NMR ((D₆)DMSO): 182.6 (C=O); 135.8 (C=S); 131.3, 121.3 (C(4'), C(5')); 130.2 (1 arom. C); 129.5, 128.7, 127.7 (5 arom. CH); 126.8 (C(2')); 48.7 (CH₂N); 31.4 (MeN); 9.8 (Me). HR-ESI-MS: 320.1174 ([*M*+H]⁺, C₁₄H₁₉N₅O₂S; calc. 320.1103).

10. *Synthesis of 1-Benzyl-4-(4,5-dihydro-4-methyl-5-thioxo-1H-1,2,4-triazol-3-yl)-5-methyl-1H-imidazole 3-Oxide (11)*. A mixture of **10** (320 mg, 1 mmol) and a 2% aq. soln. of NaOH (5 ml) was heated to reflux for 2 h. Then, the soln. was neutralized with AcOH and the formed precipitate was filtered off and crystallized from MeOH. Yield of **11**: 0.217 g (72%). Colorless crystals. M.p. 244–248° (MeOH). IR (KBr): 3161_s (NH), 1564_m, 1457_m, 1341_m, 698_m. ¹H-NMR ((D₆)DMSO): 14.02 (br. *s*, NH); 8.58 (*s*, H–C(2)); 7.43–7.29 (*m*, 5 arom. H); 5.23 (*s*, CH₂N); 3.50 (*s*, MeN); 2.14 (*s*, Me). ¹³C-NMR ((D₆)DMSO): 168.1 (C=S); 142.6 (triazol C(3)); 136.1, 118.0

(imidazole C(4), C(5)); 129.5, 128.63, 127.8 (5 arom. CH); 128.60 (1 arom. C); 126.5 (imidazole C(2)); 49.2 (CH₂N); 31.7 (MeN); 9.4 (Me). HR-ESI-MS: 302.1068 ([M+H]⁺, C₁₄H₁₆N₅OS; calc. 302.0997).

11. *Synthesis of 1-Benzyl-5-methyl-4-(5-methylamino-1,3,4-thiadiazol-2-yl)-1H-imidazole 3-Oxide (12)*. A soln. of **10** ((320 mg, 1 mmol) in conc. H₂SO₄ (5 ml) was kept at r.t. for 1 d. After neutralization of the soln. with diluted NH₄OH, the solid product was filtered off, dried, and crystallized from MeOH. Yield of **12**: 0.162 g (54%). Yellowish crystals. M.p. 214–216° (decomp., MeOH). IR (KBr): 3201*m* (br.), 3127*s*, 2963*s* (br.), 1517*m*, 1261*m*, 1096*m*, 1031*m*, 800*m*. ¹H-NMR ((D₆)DMSO): 8.57 (*s*, H–C(2)); 7.52 (br. *s*, NH); 7.41–7.26 (*m*, 5 arom. H); 5.24 (*s*, CH₂N); 2.89 (*d*, *J* = 4.8, MeN); 2.49 (*s*, Me). ¹³C-NMR ((D₆)DMSO): 169.9, 144.7 (thiadiazol C(2), C(5)); 136.3, 123.0 (imidazole C(4), C(5)); 129.4, 128.5, 127.6 (5 arom. CH); 125.3 (imidazole C(2)); 124.0 (1 arom. C); 48.9 (CH₂N); 31.7 (MeN); 10.1 (Me). HR-ESI-MS: 302.1068 ([M+H]⁺, C₁₄H₁₆N₅OS; calc. 302.1076).

12. *X-Ray Crystal Structure Determination of 1b (Table and Figure)⁴*. All measurements were made on an *Agilent Technologies SuperNova* area-detector diffractometer [20] using MoK_α radiation ($\lambda = 0.71073 \text{ \AA}$) from a micro-focus X-ray source and an *Oxford Instruments Cryojet XL* cooler. Data reduction was performed with *CrysAlisPro* [20]. The intensities were corrected for *Lorentz* and polarization effects, and an empirical absorption correction using spherical harmonics [20] was applied. The space group was determined from packing considerations, a statistical

⁴) CCDC-838434 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the *Cambridge Crystallographic Data Centre*, via www.ccdc.cam.ac.uk/data_request/cif.

analysis of intensity distribution, and the successful solution and refinement of the structure. Equivalent reflections were merged. The data collection and refinement parameters are given in the *Table*. A view of the molecule is shown in the *Figure*. The structure was solved by direct methods using *SHELXS97* [21], which revealed the positions of all non-H-atoms. The non-H-atoms were refined anisotropically. The hydrazide H-atoms were placed in the positions indicated by a difference electron density map and their positions were allowed to refine together with individual isotropic displacement parameters. All remaining H-atoms were placed in geometrically calculated positions and refined by using a riding model where each H-atom was assigned a fixed isotropic displacement parameter with a value equal to $1.2U_{eq}$ of its parent C-atom ($1.5U_{eq}$ for the Me group). The refinement of the structure was carried out on F^2 by using full-matrix least-squares procedures, which minimized the function $\sum w(F_o^2 - F_c^2)^2$. The weighting scheme was based on counting statistics and included a factor to downweight the intense reflections. A correction for secondary extinction was applied. Neutral atom scattering factors for non-H-atoms were taken from [22a], and the scattering factors for H-atoms were taken from [23]. Anomalous dispersion effects were included in F_c [24]; the values for f' and f'' were those of [22b]. The values of the mass attenuation coefficients are those of [22c]. The *SHELXL97* program [25] was used for all calculations.

Table. *Crystallographic Data for Compound 1b*

REFERENCES

- [1] a) G. Mlostoń, T. Gendek, H. Heimgartner, *Helv. Chim. Acta* **1998**, *81*, 1585; b) G. Mlostoń, M. Jasiński, A. Linden, H. Heimgartner, *Helv. Chim. Acta* **2006**, *89*, 1304; c) M. Jasiński, G. Mlostoń, P. Mucha, A. Linden, H. Heimgartner, *Helv. Chim. Acta* **2007**, *90*, 1765; d) P. Mucha, G. Mlostoń, M. Jasiński, A. Linden, H. Heimgartner, *Tetrahedron:Asymmetry* **2008**, *19*, 1600; e) M. Jasiński, G. Mlostoń, A. Linden, H. Heimgartner, *Helv. Chim. Acta*, **2008**, *91*, 1916; f) G. Mlostoń, J. Romański, M. Jasiński, H. Heimgartner, *Tetrahedron:Asymmetry* **2009**, *20*, 1073; g) M. Jasiński, G. Mlostoń, *Coll. Czech. Chem. Commun.* **2010**, *75*, 871; h) M. Jasiński, G. Mlostoń, H. Heimgartner, *J. Heterocycl. Chem.* **2010**, *47*, 1287.
- [2] G. Aguirre, M. Boiani, H. Cerecetto, A. Gerpe, M. Gonzàles, Y. Fernandez Sainz, A. Denicola, C. Ochoa De Ocàriz, J. J. Nogal, D. Montero, J. A. Escario, *Arch. Pharm. (Weinheim)* **2004**, *337*, 259.
- [3] G. Wagner, S. Laufer, *Med. Res. Rev.* **2006**, *26*, 1.
- [4] S. Laufer, G. Wagner, D. Kotschenreuther, *Angew. Chem. Int. Ed.* **2002**, *41*, 2290; S. A. Laufer, W. Zimmermann, K. J. Ruff, *J. Med. Chem.* **2004**, *47*, 6311; M.-E. Theoclitou, N. G. J. Delaet, L. A. Robinson, *J. Comb. Chem.* **2002**, *4*, 315.
- [5] L.-C. Campeau, D. R. Stuart, J.-P. Leclerc, M. Bertrand-Laperle, E. Villemure, H.-Y. Sun, S. Lasserre, N. Guimond, M. Lecavallier, K. Fagnou, *J. Am. Chem. Soc.* **2009**, *131*, 3291.
- [6] P. Kwiatkowski, P. Mucha, G. Mlostoń, J. Jurczak, *Synlett* **2009**, 1757.
- [7] a) S. Rollas, Ş. G. Küçükgülzel, *Molecules* **2007**, *12*, 1910; b) H. A. Abel-Aziza, B. F. Abel-Wahab, F. A. Badira, *Arch. Pharm. (Weinheim)* **2010**, *343*, 152; c) L. Zheng, L. Wub, B. Zhao, W. Dong, J. Miao, *Bioorg. Med. Chem.* **2009**, *17*,

- 1957; d) Y. Xia, C. Fan, B. Zhao, J. Zhao, D. Shin, J. Miao, *Eur. J. Med. Chem.* **2008**, *43*, 2347; e) J. R. Dimmocka, S. C. Vashishthaa, J. P. Stablesb, *Eur. J. Med. Chem.* **2000**, 241.
- [8] a) B. Narasimhan, P. Kumar, D. Sharma, *Acta Pharm. Sci.* **2010**, *52*, 169; b) B. Chandrakantha, P. Shetty, V. Nambiyar, N. Isloor, A. M. Isloor, *Eur. J. Med. Chem.* **2010**, *45*, 1206; c) A. Reichelt, J. R. Falsey, R. M. Rzasa, O. R. Thiel, M. M. Achmatowicz, R. D. Larsen, D. Zhang, *Org. Lett.* **2010**, *12*, 792; S. M. Abd-alla, M. I. Hegab, N. A. Abo-Taleb, S. M. Hasabelnaby, A. Goudah, *Eur. J. Med. Chem.* **2010**, 1267.
- [9] a) A. Deep, S. Jain, P. C. Sharma, P. Verma, M. Kumar, C. P. Dora, *Acta Polon. Pharm.* **2010**, *67*, 255; b) A. A. Kadi, N. R. El-Brollosy, O. A. Al-Deeb, E. E. Habib, T. M. Ibrahim, A. A. El-Emam, *Eur. J. Med. Chem.* **2007**, 235. c) A. Maliszewska-Guz, M. Wujec, M. Pitucha, M. Dobosz, A. Chodkowska, E. Jagiełło-Wójtowicz, L. Mazur, A. E. Koziół, *Collect. Czech. Chem. Commun.* **2005**, *70*, 51.
- [10] G. Mlostoń, M. Jasiński, *Arkivoc* **2011**, (vi), 162.
- [11] C.K. Johnson, *ORTEP II*, Report ORNL-5138, Oak Ridge National Laboratory, Oak Ridge, Tennessee, 1976.
- [12] J. Bernstein, R. E. Davis, L. Shimoni, N.-L. Chang, *Angew. Chem. Int. Ed. Engl.* **1995**, *34*, 1555.
- [13] C. A. M. Fraga, E. J. Barreiro, *Curr. Med. Chem.* **2006**, *13*, 167; K. Leonard, T. Lu, R. W. Tuman, D. L. Johnson, A. C. Maroney, J. L. Sechler, R. W. Connors, R. S. Alexander, M. D. Cummings, R. W. Galemme, T. P. Markotan (Janssen Pharmaceutica N. V., Belg.), WO 2006101937 A1 (*Chem. Abstr.* **2006**, *145*, 377195); M. M. Andrade, M. T. Barros, *J. Comb. Chem.* **2010**, *12*, 245; C. M.

- Moldovan, O. Oniga, A. Pârvu, B. Tiperciuc, P. Verite, A. Pîrnau, O. Drisan, M. Bojita, R. Pop, *Eur. J. Med. Chem.* **2011**, *46*, 526.
- [14] A. Siwek, J. Stefańska, I. Wawrzycka-Gorczyca, M. Wujec, *Heteroatom. Chem.* **2010**, *21*, 131; V. Mickevicius, V. Intaite, A. Voskiene, K. Kantminiene, M. Stasevych, O. Komorovska-Porokhnyavets, V. Novikov, *Heterocycles* **2010**, *81*, 649.
- [15] J. H. M. Lange, H. H. Van Stuivenberg, H. K. A. C. Coolen, T. J. P. Adolfs, A. C. McCreary, H. G. Keizer, H. C. Wals, W. Veerman, A. J. M. Borst, W. de Looft, P. C. Verveer, C. G. Kruse, *J. Med. Chem.* **2005**, *48*, 1823.
- [16] S. Shukla, M. Bhalla, U. Misra, D. Mukerjee, A. K. Saxsena, J. N. Sinha, K. Shanker, *Boll. Chim. Farmac.* **1998**, *137*, 229.
- [17] Takeda Chemical Industries, Ltd., **1998**, US 5753664 A1; Solvay Pharmaceuticals B. V., **2005**, US 2005/54679 A1; L. Cheng (Astrazeneca AB), PCT Int. Appl. (2007), WO 2007031721 A1 (*Chem. Abstr.* **2007**, *146*, 358846).
- [18] a) A. P. Krapcho, D. R. Rao, M. P. Silvon, B. Abegaz, *J. Org. Chem.* **1971**, *36*, 3885; b) G. Mlostoń, M. Celeda, A. Linden, H. Heimgartner, *Pol. J. Chem.* **2004**, *78*, 2089.
- [19] H. Heimgartner, G. Mloston, in 'Electronic Encyclopedia of Reagents in Organic Synthesis', L. Paquette, J. Rigby, D. Crich and P. Wipf, eds., John Wiley & Sons, Chichester, West Sussex, PO19 8SQ, UK, Article RN00430.
- [20] *CrysAlisPro*, Version 1.171.34.49, Agilent Technologies, Yarnton, Oxfordshire, England, 2011.
- [21] G. M. Sheldrick, *Acta Crystallogr. Sect. A* **2008**, *64*, 112.
- [22] a) E. N. Maslen, A. G. Fox, M. A. O'Keefe, in 'International Tables for Crystallography', Ed. A. J. C. Wilson, Kluwer Academic Publishers, Dordrecht,


1992, Vol. C, Table 6.1.1.1, pp. 477-486; b) D. C. Creagh, W. J. McAuley, in 'International Tables for Crystallography', Ed. A. J. C. Wilson, Kluwer Academic Publishers, Dordrecht, 1992, Vol. C, Table 4.2.6.8, pp. 219-222; c) D. C. Creagh, J. H. Hubbell, in 'International Tables for Crystallography', Ed. A. J. C. Wilson, Kluwer Academic Publishers, Dordrecht, 1992, Vol. C, Table 4.2.4.3, pp. 200-206.

- [23] R. F. Stewart, E. R. Davidson, W. T. Simpson, *J. Chem. Phys.* **1965**, *42*, 3175.
- [24] J. A. Ibers, W. C. Hamilton, *Acta Crystallogr.* **1964**, *17*, 781.
- [25] G. M. Sheldrick, SHELXL97, Program for the Refinement of Crystal Structures, University of Göttingen, Germany, 1997.


Table. *Crystallographic Data for Compound 1b*

Crystallized from	MeOH
Empirical formula	C ₁₂ H ₁₄ N ₄ O ₂
Formula weight [g mol ⁻¹]	246.27
Crystal color, habit	pale-yellow, prism
Crystal dimensions [mm]	0.28 × 0.30 × 0.30
Temperature [K]	160(1)
Crystal system	triclinic
Space group	\bar{P} , 1
Z	2
Reflections for cell determination	7053
2 θ range for cell determination [°]	5–59
Unit cell parameters	
<i>a</i> [Å]	6.8168(2)
<i>b</i> [Å]	7.6666(2)
<i>c</i> [Å]	11.7286(4)
α [°]	97.379(3)
β [°]	93.255(3)
γ [°]	101.516(3)
<i>V</i> [Å ³]	593.49(3)
<i>D_x</i> [g cm ⁻³]	1.378
$\mu(\text{MoK}\alpha)$ [mm ⁻¹]	0.0977
Scan type	ω
2 $\theta_{(\text{max})}$ [°]	58.5
Transmission factors (min; max)	0.855; 1.000
Total reflections measured	10252
Symmetry independent reflections	2815
Reflections with $I > 2\sigma(I)$	2618
Reflections used in refinement	2815
Parameters refined	177
Final $R(F)$ [$I > 2\sigma(I)$ reflections]	0.0412
$wR(F^2)$ (all data)	0.1054
Weights:	$w = [\sigma^2(F_o^2) + (0.0466P)^2 + 0.2729P]^{-1}$ where $P = (F_o^2 + 2F_c^2)/3$
Goodness of fit	1.038
Secondary extinction coefficient	0.013(4)
Final $\Delta_{\text{max}}/\sigma$	0.001
$\Delta\rho$ (max; min) [e Å ⁻³]	0.33; -0.41


Scheme 1




Scheme 2





Scheme 3




Scheme 4




Scheme 5

**8a** $\text{R}^1 = \text{Bn}$, $\text{R}^2 = \text{H}$, $\text{R}^3 = \text{Ph}$ **b** $\text{R}^1 = \text{cHex}$, $\text{R}^2 = \text{H}$, $\text{R}^3 = \text{Ph}$ **c** $\text{R}^1 = \text{Bn}$, $\text{R}^2\text{-R}^3 = \text{Ad}$ **d** $\text{R}^1 = \text{cHex}$, $\text{R}^2\text{-R}^3 = \text{Ad}$ **e** $\text{R}^1 = \text{Bn}$, $\text{R}^2\text{-R}^3 = -(\text{CH}_2)_5-$ **f** $\text{R}^1 = \text{cHex}$, $\text{R}^2\text{-R}^3 = -(\text{CH}_2)_5-$ **g** $\text{R}^1 = \text{Bn}$, $\text{R}^2 = \text{Me}$, $\text{R}^3 = \text{Ph}$ **h** $\text{R}^1 = \text{cHex}$, $\text{R}^2 = \text{Me}$, $\text{R}^3 = \text{Ph}$ **9a** $\text{R}^1 = \text{Bn}$, $\text{R}^2 = \text{Me}$, $\text{R}^3 = \text{H}$, $\text{R}^4 = 4\text{-MeOC}_6\text{H}_4$ **b** $\text{R}^1 = \text{Bn}$, $\text{R}^2 = \text{Me}$, $\text{R}^3 = \text{H}$, $\text{R}^4 = 4\text{-Me}_2\text{NC}_6\text{H}_4$ **c** $\text{R}^1 = \text{Bn}$, $\text{R}^2 = \text{Me}$, $\text{R}^3\text{-R}^4 = -(\text{CH}_2)_5-$ **d** $\text{R}^1 = \text{cHex}$, $\text{R}^2 = \text{Me}$, $\text{R}^3 = \text{H}$, $\text{R}^4 = 4\text{-MeSC}_6\text{H}_4$ **e** $\text{R}^1 = \text{cHex}$, $\text{R}^2 = \text{Me}$, $\text{R}^3 = \text{H}$, $\text{R}^4 = 4\text{-MeOC}_6\text{H}_4$ **f** $\text{R}^1 = \text{Bn}$, $\text{R}^2 = \text{Ph}$, $\text{R}^3 = \text{H}$, $\text{R}^4 = 4\text{-MeSC}_6\text{H}_4$ **g** $\text{R}^1 = \text{Bn}$, $\text{R}^2 = \text{Ph}$, $\text{R}^3\text{-R}^4 = -(\text{CH}_2)_5-$


Scheme 6



Scheme 7



Figure



Graphical Abstract